Lysosomal dysfunction in Gaucher disease (GD) leads to inflammation, impaired cellular homeostasis, and disrupted autophagy. The alteration in immune system and the pro-inflammatory state in GD involves in the pathogenesis of the disease with increased levels of cytokines and chemokines. In this study, we aimed to analyze immunological abnormalities and association with HLA alleles in GD patients. Whole blood count, lyso-Gb3 levels, and immunological status were evaluated. A total of 13 patients confirmed to have GD were enrolled in our study. The most common positive antibody was anti-CCP and ANA. Only one patient’s HLA profile was predisposing to autoimmune disease but had no clinical findings. None of the patients had symptoms of any related diseases with detected immunological markers. In our study, clinical status of GD or HLA alleles were not associated with positive markers of autoimmune diseases. Further studies are needed to elucidate inflammatory mechanism in GD.
ZimranA. Gaucher disease and related lysosomal storage diseases. In: KaushanskyK, ed. Williams Hematology. 9th ed. New York: McGraw-Hill Education; 2016:1121-1133.
2.
FerrazMJ.Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys Acta. 2014;1841:811-825. doi:10.1016/j.bbalip.2013.11.004.
3.
SidranskyE.Gaucher disease: insights from a rare Mendelian disorder. Discov Med. 2012;14(77):273-281.
4.
BoshM.Neuroinflammatory paradigms in lysosomal storage diseases. Front Neurosci. 2005;9:417. doi:10.3389/fnins.2015.00417.
5.
RiganteDCipollaCBasileUGulliFSavastanoMC.Overview of immune abnormalities in lysosomal storage disorders. Immunol Lett. 2017;188:79-85. doi:10.1016/j.imlet.2017.07.004.
6.
SettembreCFraldiARubinszteinDCBallabioA.Lysosomal storage diseases as disorders of autophagy. Autophagy. 2008;4(1):113-114. doi:10.4161/auto.5227.
7.
MattaMCVairoFTorresLCSchwartzI.Could enzyme replacement therapy promote immune tolerance in Gaucher disease type 1. Blood Cells Mol Dis. 2018;68:200-202. doi:10.1016/j.bcmd.2016.10.016.
8.
BarakVAckerMNismanB, et alCytokines in Gaucher’s disease. Eur Cytokine Netw. 1999;10:205-210.
9.
AllenMJMyerBJKhokherAMRushtonNCoxTM.Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. QJM. 1997;90(1):19-25. doi:10.1093/qjmed/90.1.19.
10.
HollakCEEversLAertsJMvan OersMH.Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis. 1997;23(2):201-212. doi:10.1006/bcmd.1997.0137.
11.
van BreemenMJde FostMVoermanJS, et alIncreased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta. 2007;1772(7):788-796. doi:10.1016/j.bbadis.2007.04.002.
12.
PandeyMKBurrowTARaniR, et alComplement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease. Nature. 2017;543(7643):108-112. doi:10.1038/nature21368.
13.
ZahranAMEltayebAAElsayhKISaadKAhmadFAIbrahimAIM. Activated and memory T lymphocytes in children with Gaucher disease. Arch Immunol Ther Exp (Warsz). 2017;65(3):263-269. doi:10.1007/s00005-016-0421-y.
14.
ShoenfeldYGallantLAShaklaiMLivniEDjaldettiMPinkhasJ.Gaucher’s disease: a disease with chronic stimulation of the immune system. Arch Pathol Lab Med. 1982;106(8):388-391.
15.
ShoenfeldYBeresovskiAZharharyD, et alNatural autoantibodies in sera of patients with Gaucher’s disease. J Clin Immunol. 1995;15:363-372. doi:10.1007/BF01541326.
16.
ShererYDulitzkiMLevyYLivnehAShoenfeldYLangevitzP.Successful pregnancy outcome in a patient with Gaucher’s disease and antiphospholipid syndrome. Ann Hematol. 2002;81(3):161-163. doi:10.1007/s00277-002-0431-1.
Le PeilletDPrendkiVTrombertV, et alType I Gaucher disease with bullous pemphigoid and Parkinson disease: a case report. Medicine (Baltimore). 2018;97(13):e0188. doi:10.1097/MD.0000000000010188.
19.
JerónimoTCabritaAPimentelA, et alGaucher disease and Lupus: a rare association. Nefrologia. 2016;36(6):719-721. doi:10.1016/j.nefro.2016.05.014.
20.
SerratriceCBensalahNPenarandaG, et alPrevalence of autoantibodies in the course of Gaucher disease type 1: a multicenter study comparing Gaucher disease patients to healthy subjects. Joint Bone Spine. 2018;85(1):71-77. doi:10.1016/j.jbspin.2016.12.002.
21.
LesterTJGrabowskiGAGoldblattJLeidermanIZZaroulisCG.Immune thrombocytopenia and Gaucher’s disease. Am J Med. 1984;77(3):569-571. doi:10.1016/0002-9343(84)90124-4.
22.
MattaMCSoaresDCKerstenetzkyMSFreitasACKimCATorresLC.CD4+CD25 high Foxp3+ Treg deficiency in a Brazilian patient with Gaucher disease and lupus nephritis. Hum Immunol. 2016;77(2):196-200. doi:10.1016/j.humimm.2015.11.018.
23.
GoughSCSimmondsMJ.The HLA region and autoimmune disease: associations and mechanisms of action. Curr Genomics. 2007;8(7):453-465. doi:10.2174/138920207783591690.
24.
MikkMLKiviniemiMLaineAP, et al; Finnish Paediatric Diabetes Register. The HLA-B*39 allele increases type 1 diabetes risk conferred by HLA-DRB1*04:04-DQB1*03:02 and HLA-DRB1*08-DQB1*04 class II haplotypes. Hum Immunol. 2014;75(1):65-70. doi:10.1016/j.humimm.2013.09.008.
25.
PopperudTHVikenMKKertyELieBA.Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset. PLoS ONE. 2017;12(10):e0186383. doi:10.1371/journal.pone.0186383.
